ustekinumab psoriasis
Selected indexed studies
- Ustekinumab for the treatment of psoriasis: an evidence update. (Semin Cutan Med Surg, 2018) [PMID:30215630]
- A non-clinical comparative study of IL-23 antibodies in psoriasis. (MAbs, 2021) [PMID:34460338]
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. (J Am Acad Dermatol, 2015) [PMID:26092291]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. (2015) pubmed
- A non-clinical comparative study of IL-23 antibodies in psoriasis. (2021) pubmed
- Ustekinumab for the treatment of psoriasis: an evidence update. (2018) pubmed
- Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report. (2024) pubmed
- Ustekinumab for the treatment of psoriasis. (2011) pubmed
- The efficacy of ustekinumab in psoriasis. (2013) pubmed
- Ustekinumab for psoriasis and psoriatic arthritis. (2012) pubmed
- The safety of ustekinumab in psoriasis. (2012) pubmed
- Morphea in patients with psoriasis treated with ustekinumab: a scoping review. (2024) pubmed
- Pyzchiva (ustekinumab-ttwe): A New Biosimilar for Psoriasis. (2026) pubmed